Atezolizumab

Overall treatment outcomes among patients with extensive-stage small cell lung cancer who received first-line chemoimmunotherapy appeared comparable to those reported in pivotal clinical trials, according to study results.

SAN FRANCISCO — Atezolizumab monotherapy improved OS compared with chemotherapy among patients with PD-L1-high, cisplatin-ineligible metastatic urothelial carcinoma, according to an exploratory analysis of a randomized phase 3 study.

SAN FRANCISCO — The addition of atezolizumab to platinum-based chemotherapy failed to significantly improve survival for patients with metastatic urothelial carcinoma, according to a final analysis of the randomized phase 3 IMvigor130 trial.

Adjuvant therapy with atezolizumab and bevacizumab reduced recurrence risk compared with active surveillance for patients with certain types of early-stage liver cancer, according to topline data released by the agents’ manufacturer.

Cervical Cancer Awareness Month is observed every January.

The addition of atezolizumab to bevacizumab showed promising efficacy among patients with nonsquamous non-small cell lung cancer with high tumor mutational burden, according to results of a phase 2 trial published in JAMA Oncology.

The FDA approved atezolizumab for adults and children aged 2 years or older with unresectable or metastatic alveolar soft part sarcoma.

The triplet combination of vemurafenib/cobimetinib/atezolizumab showed improvement in overall survival in patients with BRAF-mutated anaplastic thyroid cancer, according to research presented at American Thyroid Association Annual Meeting.

Roche voluntarily withdrew atezolizumab’s indication in the United States for the treatment of adults with locally advanced or metastatic urothelial carcinoma.

At this year’s International Association for the Study of Lung Cancer World Conference on Lung Cancer, one of the more talked about presentations was IMpower010.